FDA clears DiA's cardiac ultrasound AI

By AuntMinnie.com staff writers

October 29, 2020 -- Echocardiography image analysis software developer DiA Imaging Analysis has received clearance from the U.S. Food and Drug Administration (FDA) for its LVivo Seamless cardiac ultrasound artificial intelligence (AI) software.

LVivo chooses the best cardiac ultrasound views from standard echocardiogram exams and works with the company's other LVivo offerings such as LVivo EF for automated calculation of ejection fraction, it said.

DiA plans to highlight LVivo at the upcoming virtual RSNA meeting.

DiA gets FDA nod, CE Mark for AI-based ultrasound tools
Echocardiography image analysis software developer DiA Imaging Analysis has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the...
DiA gets Israel government grant for COVID-19
Echocardiography image analysis software developer DiA Imaging Analysis has received a grant from the government of Israel to develop artificial intelligence...
DiA partners with IBM Watson on AI
Echocardiography image analysis software developer DiA Imaging Analysis announced its collaboration with IBM Watson Health on artificial intelligence...
DiA Imaging joins forces with Edan Instruments
Ultrasound artificial intelligence software developer DiA Imaging Analysis has inked a partnership with ultrasound technology developer Edan Instruments.

Copyright © 2020 AuntMinnie.com